To include your compound in the COVID-19 Resource Center, submit it here.

IV Baxdela delafloxacin: Phase III data

Top-line data from the double-blind, international Phase III RX-3341-303 trial in 850 patients with ABSSSIs showed that IV-to-oral Baxdela met the FDA-defined primary endpoint of non-inferiority to standard of care (SOC)

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE